Although the role of GSDMD in the pathogenesis of NAFLD and the potential underlying mechanisms remain unclear, GSDMD represents a potential therapeutic target or biomarker of disease progression for human NAFLD that deserves further attention in the future 63. The gene discussed is GSDMD; the disease is metabolic dysfunction-associated steatotic liver disease.